Sökning: "Anna Åleskog"

Hittade 3 avhandlingar innehållade orden Anna Åleskog.

  1. 1. Application of In Vitro Chemosensitivity Testing for Evaluation of New Cytotoxic Drugs in Chronic Lymphocytic Leukaemia

    Författare :Anna Åleskog; Jan Liliemark; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Clinical drug development; chronic lymphocytic leukaemia; cytotoxicity; in vitro assay; cytotoxic drug development; CHS 828; IgVH mutation status; Klinisk läkemedelsutveckling; Pharmaceutical chemistry; Läkemedelskemi; Clinical Pharmacology; klinisk farmakologi;

    Sammanfattning : Despite major advances in the understanding of the biology of chronic lymphocytic leukaemia (CLL), progress in improving its treatment has been limited and it still remains an incurable disorder. In the present research, we have performed in vitro drug sensitivity testing of primary CLL cells for preclinical evaluation of cytotoxic drugs, using the fluorometric microculture cytotoxicity assay (FMCA). LÄS MER

  3. 2. Integrating Efficacy and Toxicity in Preclinical Anticancer Drug Development : Methods and Applications

    Författare :Caroline Haglund; Elin Lindhagen; Rolf Larsson; Anna Åleskog; Sigurd Vitols; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Anticancer drugs; In vitro assays; Toxicity testing; Haematological toxicity; Primary tumour cells; Species difference; Clinical pharmacology; Klinisk farmakologi; Clinical Pharmacology; Klinisk farmakologi;

    Sammanfattning : Preclinical testing is an important part of cancer drug development. The aim of this thesis was to establish and evaluate preclinical in vitro methods useful in the development of new anticancer drugs. In paper I, the development of non-clonogenic assays (FMCA-GM) using CD34+ stem cells for assessment of haematological toxicity was described. LÄS MER

  4. 3. In Vitro Drug Sensitivity and Apoptosis in Chronic Lymphocytic Leukemia

    Författare :Maria Norberg; Richard Rosenquist; Anna Åleskog; Elin Lindhagen; Gerard Tobin; Per-Ola Andersson; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; chronic lymphocytic leukemia; in vitro drug sensitivity; apoptosis; prognostic markers; Clinical genetics; Klinisk genetik; Haematology; Hematologi; Molecular medicine genetics and pathology ; Molekylär medicin genetik och patologi ; MEDICINE; MEDICIN; Medical genetics; Medicinsk genetik; Medical Science; Medicinsk vetenskap; Clinical Genetics; Klinisk genetik; Molekylär genetik; Molecular Genetics; Medical Genetics; Medicinsk genetik; Molekylär medicin; Molecular Medicine;

    Sammanfattning : Chronic lymphocytic leukemia (CLL) is a heterogeneous malignancy displaying varying clinical outcome, where molecular markers today can divide patients into prognostic subgroups. Despite the introduction of new agents for treatment, remissions are usually not sustained in CLL and resistance towards treatment can partly be explained by aberrant apoptosis. LÄS MER